<p>A new paper <a href="https://www.science.org/doi/10.1126/sciadv.adi5921"><u>published in </u><em><u>Science Advances</u></em></a><em> </em>clarifies how an enzyme called SMYD3 may be involved in prostate cancer’s progression to a more dangerous and aggressive stage. The enzyme’s newly confirmed role makes it a prime potential drug target for preventing metastatic disease, especially given that SMYD3 inhibitors already exist. The new work’s conclusions about SMYD3’s mechanism differ from some previous studies of SMYD3 and reveal new details, opening new research directions.</p>